An oral candidate for the treatment of hereditary angioedema (HAE) has begun a phase 1 clinical trial, KalVista Pharmaceuticals recently announced. HAE is a rare genetic disease characterized by recurrent episodes of severe swelling (angioedema) and potential pain, nausea, and vomiting. It occurs in about 1 in 10,000 to 1…
News
The U.S. Food and Drug Administration (FDA) has agreed to review Pharming’s application to get Ruconest (conestat alfa) approved for the routine prevention of swelling attacks caused by hereditary angioedema (HAE). The therapy already is approved for the acute treatment of swelling attacks in adults and adolescents with…
Recent Posts
- HAE treatment for preventing swelling attacks wins approval in Canada
- Recurring, severe abdominal pain may be sign of angioedema in children
- Discovering the importance of writing down explicit instructions
- New trial data show lasting cuts in HAE attacks with long-acting drug
- The joy of meeting fellow members of the Bionews family